|
||||||||||||||||||||||||||
| SEC Info | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For/On/As Docs:Size Issuer Agent 8/28/12 Ziopharm Oncology Inc 10-Q/A 6/30/12 50:3.1M Vintage Filings/FA
Document/Exhibit Description Pages Size
1: 10-Q/A Amendment to Quarterly Report HTML 29K
2: EX-31.1 Certification per Sarbanes-Oxley Act (Section 302) HTML 20K
3: EX-31.2 Certification per Sarbanes-Oxley Act (Section 302) HTML 20K
4: EX-32.1 Certification per Sarbanes-Oxley Act (Section 906) HTML 18K
49: XML XBRL XML File -- Filing Summary XML 78K
32: R1 Document and Entity Information HTML 37K
23: R2 Balance Sheets HTML 124K
30: R3 Balance Sheets (Parenthetical) HTML 42K
34: R4 Statements Of Operations HTML 74K
46: R5 Statement Of Stockholders' Equity HTML 74K
24: R6 Statement Of Stockholders' Equity (Parenthetical) HTML 18K
29: R7 Statements of Cash Flows HTML 154K
21: R8 Business HTML 25K
15: R9 Summary of Significant Accounting Policies HTML 21K
47: R10 Collaborations and Alliances HTML 21K
36: R11 Fair Value Measurements HTML 36K
35: R12 Net Loss per Share HTML 23K
40: R13 Related Party Transactions HTML 23K
41: R14 Commitments and Contingencies HTML 51K
39: R15 Warrants HTML 46K
42: R16 Common Stock HTML 19K
31: R17 Stock-Based Compensation HTML 38K
33: R18 Fair Value Measurements (Tables) HTML 24K
38: R19 Net Loss per Share (Tables) HTML 21K
50: R20 Warrants (Tables) HTML 36K
44: R21 Stock-Based Compensation (Tables) HTML 42K
26: R22 Business - Additional Information (Detail) HTML 25K
37: R23 Collaborations and Alliances - Additional HTML 24K
Information (Detail)
28: R24 Assets and Liabilities Measured at Fair Value on HTML 26K
Recurring Basis (Detail)
13: R25 Potential Dilutive Shares Excluded from HTML 27K
Computation of Diluted Net Loss Per
Share (Detail)
45: R26 Related Party Transactions - Additional HTML 29K
Information (Detail)
48: R27 Commitments and Contingencies - Additional HTML 122K
Information (Detail)
18: R28 Number of Warrants Outstanding (Detail) HTML 21K
17: R29 Warrants - Additional Information (Detail) HTML 74K
19: R30 Assumptions Used In Binomial Valuation Model and HTML 25K
Black-Scholes Valuation Model (Detail)
20: R31 Warrant Exercise (Detail) HTML 31K
22: R32 Common Stock - Additional Information (Detail) HTML 35K
11: R33 Stock-Based Compensation Expense on All Employee HTML 23K
and Non-Employee Awards (Detail)
43: R34 Stock-Based Compensation - Additional Information HTML 32K
(Detail)
25: R35 Fair Value of Stock Options Assumptions Using HTML 35K
Black-Scholes Option Valuation Model
(Detail)
27: R36 Stock Option Activity Under Stock Option Plan HTML 86K
(Detail)
14: R37 Summary of Unvested Restricted Stock (Detail) HTML 48K
16: EXCEL XBRL IDEA Workbook -- Financial Report XLS 392K
5: EX-101.INS XBRL Instance -- ziop-20120630 XML 724K
7: EX-101.CAL XBRL Calculations -- ziop-20120630_cal XML 104K
8: EX-101.DEF XBRL Definitions -- ziop-20120630_def XML 610K
9: EX-101.LAB XBRL Labels -- ziop-20120630_lab XML 902K
10: EX-101.PRE XBRL Presentations -- ziop-20120630_pre XML 686K
6: EX-101.SCH XBRL Schema -- ziop-20120630 XSD 143K
12: ZIP XBRL Zipped Folder -- 0001144204-12-048414-xbrl ZIP 101K
|
Related Party Transactions
|
106 Months Ended |
|---|---|
| Related Party Transactions | 6. Related Party Transactions
On January 6, 2011, the Company entered into an Exclusive Channel Partner Agreement (the “Channel Agreement”) with Intrexon Corporation (see Note 7 for additional disclosure relating to the Channel Agreement). During the six months ended June 30, 2012, the Company paid Intrexon approximately $10.7 million, of which $2.5 million was for services already incurred and the remaining $8.2 million expected to be incurred within a year. This amount has been included as part of prepaid expenses and other current assets on the accompanying balance sheet as of June 30, 2012. The Company does not owe any amounts to Intrexon that have not already been accrued for as of June 30, 2012.
On January 25, 2012, Intrexon purchased 1,923,075 shares of common stock in the Company’s public offering (see Note 9). |
| X | ||||||||||
|
- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| This 10-Q/A Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 9/15/09 | 4, 8-K | |||
| 1/6/11 | 8-K | |||
| 1/25/12 | 8-K, SC 13D/A | |||
| For The Period Ended | 6/30/12 | 10-Q | ||
| Filed On / Filed As Of | 8/28/12 | |||
| Top | List All Filings | |||